Humana Inc. (NYSE:HUM) Shares Sold by Avantax Advisory Services Inc.

Avantax Advisory Services Inc. lessened its stake in Humana Inc. (NYSE:HUM - Free Report) by 43.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,842 shares of the insurance provider's stock after selling 1,433 shares during the quarter. Avantax Advisory Services Inc.'s holdings in Humana were worth $467,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Landscape Capital Management L.L.C. boosted its holdings in Humana by 54.4% during the third quarter. Landscape Capital Management L.L.C. now owns 2,451 shares of the insurance provider's stock worth $776,000 after buying an additional 864 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Humana by 42.0% in the third quarter. Massachusetts Financial Services Co. MA now owns 391,657 shares of the insurance provider's stock worth $124,053,000 after acquiring an additional 115,820 shares during the period. Meridian Wealth Management LLC purchased a new stake in shares of Humana during the 3rd quarter worth about $1,072,000. Cerity Partners LLC boosted its stake in shares of Humana by 72.0% during the 3rd quarter. Cerity Partners LLC now owns 31,605 shares of the insurance provider's stock worth $10,011,000 after acquiring an additional 13,233 shares in the last quarter. Finally, Swedbank AB grew its position in shares of Humana by 3.0% during the 3rd quarter. Swedbank AB now owns 105,976 shares of the insurance provider's stock valued at $33,567,000 after acquiring an additional 3,085 shares during the period. Institutional investors and hedge funds own 92.38% of the company's stock.

Remove Ads

Humana Trading Down 0.2 %

HUM stock traded down $0.44 during midday trading on Thursday, hitting $270.04. 1,284,380 shares of the company's stock were exchanged, compared to its average volume of 1,599,551. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46. The business has a 50-day simple moving average of $270.63 and a two-hundred day simple moving average of $274.97. The stock has a market capitalization of $32.59 billion, a PE ratio of 27.14, a P/E/G ratio of 2.05 and a beta of 0.57. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating analysts' consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, sell-side analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.31%. The ex-dividend date of this dividend is Friday, March 28th. Humana's payout ratio is 35.58%.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on HUM shares. Morgan Stanley lowered their price target on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 12th. Barclays increased their target price on Humana from $255.00 to $270.00 and gave the company an "equal weight" rating in a research report on Thursday, February 13th. Piper Sandler boosted their price target on shares of Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a report on Wednesday, January 15th. Royal Bank of Canada restated an "outperform" rating and set a $283.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and set a $290.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Eighteen research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $285.68.

Insiders Place Their Bets

In other news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.37% of the stock is owned by insiders.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.